SecSonar.com

AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

AbCellera Biologics Inc. (ABCL) is a Biotechnology company based in CA with a market capitalization of $1.9B. Revenue grew 160.6% year-over-year and free cash flow was negative at -$174.1M. This page tracks ABCL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

CA · 596 employees · IPO Dec 11, 2020

Valuation

Valuation & price

$5.33 · as of May 26, 2026 · -34.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.94

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$8.11$5.57$3.04Jul 25Dec 25Jul 26Jul 7, 25$4.03Jul 9, 25$4.22Jul 11, 25$4.01Jul 15, 25$3.94Jul 17, 25$3.90Jul 21, 25$5.15Jul 23, 25$4.99Jul 25, 25$5.11Jul 29, 25$4.69Jul 31, 25$4.47Aug 4, 25$4.34Aug 6, 25$4.12Aug 11, 25$4.50Aug 13, 25$4.58Aug 15, 25$4.59Aug 19, 25$4.29Aug 21, 25$4.30Aug 25, 25$4.23Aug 27, 25$4.35Aug 29, 25$4.18Sep 3, 25$3.99Sep 5, 25$4.22Sep 9, 25$4.24Sep 11, 25$4.61Sep 16, 25$4.77Sep 18, 25$4.72Sep 22, 25$4.83Sep 24, 25$4.77Sep 26, 25$4.74Sep 30, 25$5.03Oct 2, 25$5.98Oct 6, 25$5.87Oct 8, 25$6.17Oct 10, 25$5.53Oct 14, 25$5.62Oct 16, 25$5.84Oct 21, 25$5.58Oct 23, 25$5.71Oct 27, 25$5.77Oct 29, 25$5.62Oct 31, 25$5.55Nov 4, 25$4.87Nov 6, 25$4.53Nov 10, 25$4.03Nov 12, 25$3.97Nov 14, 25$3.69Nov 18, 25$3.66Nov 20, 25$3.41Nov 25, 25$3.62Nov 28, 25$3.73Dec 2, 25$3.46Dec 4, 25$3.65Dec 8, 25$3.59Dec 10, 25$3.77Dec 12, 25$3.62Dec 16, 25$3.46Dec 18, 25$3.53Dec 22, 25$3.72Dec 24, 25$3.72Dec 29, 25$3.46Jan 2, 26$3.43Jan 6, 26$3.90Jan 8, 26$4.11Jan 12, 26$4.52Jan 14, 26$4.29Jan 16, 26$4.12Jan 21, 26$4.28Jan 23, 26$4.24Jan 27, 26$3.99Jan 29, 26$3.86Feb 2, 26$3.50Feb 4, 26$3.27Feb 9, 26$3.22Feb 11, 26$3.13Feb 13, 26$3.10Feb 18, 26$3.13Feb 20, 26$3.04Feb 24, 26$3.22Feb 26, 26$3.59Mar 2, 26$3.82Mar 4, 26$3.63Mar 6, 26$3.45Mar 10, 26$3.57Mar 12, 26$3.47Mar 17, 26$3.55Mar 19, 26$3.53Mar 23, 26$3.37Mar 25, 26$3.39Mar 27, 26$3.27Mar 31, 26$3.49Apr 2, 26$3.52Apr 7, 26$3.30Apr 9, 26$3.44Apr 13, 26$3.66Apr 15, 26$3.86Apr 17, 26$4.01Apr 22, 26$4.08Apr 24, 26$4.15Apr 28, 26$4.16Apr 30, 26$4.15May 4, 26$4.59May 6, 26$5.04May 8, 26$5.24May 12, 26$4.95May 14, 26$4.40May 18, 26$4.16May 20, 26$4.57May 22, 26$5.20May 28, 26$5.73Jun 1, 26$6.46Jun 3, 26$5.72Jun 5, 26$5.62Jun 9, 26$5.30Jun 11, 26$5.27Jun 15, 26$5.26Jun 17, 26$5.44Jun 22, 26$5.74Jun 24, 26$6.03Jun 26, 26$7.38Jul 2, 26$8.11
$2.7852-week range$8.12
Loading valuation history…

Fundamentals

Key fundamentals

$1.9B

Market cap

160.6%

Revenue growth (YoY)

61.6%

Gross margin

-$174.1M

Free cash flow (USD)

-$390.6M

Net debt

Net cash position

1.5%

Share dilution

2/6

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2018 → 2025

FY 2018$8.8MFY 2019$11.6MFY 2020$233.2MFY 2021$375.2MFY 2022$485.4MFY 2023$38.0MFY 2024$28.8MFY 2025$75.1M
$8.8M$75.1M

Free cash flow by year

2018 → 2025

FY 2018$-1.7MFY 2019$-1.3MFY 2020$8.0MFY 2021$186.1MFY 2022$204.7MFY 2023$-121.4MFY 2024$-187.0MFY 2025$-174.1M
-$1.7M-$174.1M

Gross margin by year

2021 → 2025

FY 202187.9%FY 202286.3%FY 2023100.0%FY 2024100.0%FY 202561.6%
87.9%61.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

1

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventCollaboration AgreementJun 17, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 12, 2026Filing
  • 8-K eventDirector AppointmentJun 5, 2026Filing
  • Insider buyInsider Buy $95KMontalbano John S. · Director · $95.4KMay 18, 2026Filing
  • 8-K eventEarnings ReleaseMay 11, 2026Filing
  • Quarterly report10-Q FiledMay 11, 2026Filing

Questions

Frequently asked questions

What is AbCellera Biologics Inc.'s market cap?

AbCellera Biologics Inc. (ABCL) has a market capitalization of $1.9B.

What is ABCL's P/E ratio?

A meaningful P/E ratio is not available for ABCL — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ABCL's price-to-book (P/B) ratio?

ABCL trades at 1.94 times book value per share.

Are insiders buying ABCL stock?

Yes — SEC Form 4 filings show 1 open-market insider buy and 0 sells at AbCellera Biologics Inc. in the last 90 days.

Same arena

Related companies in Biotechnology

GLPG

Galapagos N.V.

$1.9B

BCRX

BioCryst Pharmaceuticals, Inc.

$1.9B

ADMA

ADMA Biologics, Inc.

$1.9B

AAPG

Ascentage Pharma Group International

$1.9B

SRPT

Sarepta Therapeutics, Inc.

$1.9B

ZYME

Zymeworks Inc.

$1.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.